Skip to main content Accessibility help

Cardiac Valvulopathy Associated with Pergolide Use

  • Cindy Zadikoff (a1), Paula Rochon (a2) and Anthony Lang (a1)



To review the risk of pergolide associated cardiac valvulopathy in patients with Parkinson's disease.

Data Sources:

MEDLINE, Embase, and the Cochrane Library. Reference lists were reviewed and librarians were consulted to identify additional trials.

Study selection:

All studies and case reports in the English literature on pergolide and cardiac valvulopathy.

Data extraction:

Demographics of patients, study duration, dose and duration of pergolide use, echocardiogram results, length of follow-up, and clinical outcome.


Twenty-two published articles were identified. There were no randomized controlled trials. Follow-up time varied between a few months and four years. Three case reports and four studies (three case control and one observational) assessed 246 patients. Evidence for valvulopathy was found in all studies. Variable methods were used to assess the degree of valvular regurgitation making comparisons between studies difficult. Little clinical correlation is available for echocardiogram results. Variable improvement was shown in the few patients in whom the drug was stopped. There is insufficient data to determine whether dose and duration or other comorbities have an effect on the risk of developing cardiac valvulopathy.


Pergolide therapy is associated with an increased risk of developing cardiac valvulopathy but the true incidence and importance of this remains unknown. Further prospective studies are needed with standardized assessments of echocardiograms.

RÉSUMÉ Objectif:

Revoir le risque de valvulopathie cardiaque associée au pergolide chez les patients atteints de la maladie de Parkinson.

Source des données:

MEDLINE, Embase et The Cochrane Library. Nous avons aussi révisé des listes de références et nous avons consulté des bibliothécaires afin d'identifier des études additionnelles.

Sélection des études:

Toutes les études et les rapports de cas de la littérature en anglais sur le pergolide et la valvulopathie cardiaque.

Extraction des données:

Les données démographiques des patients, la durée des études, la dose et la durée d'utilisation du pergolide, les résultats d'échocardiographie, la durée du suivi et l'issue clinique.


Aucun essai randomisé et contrôlé ne figurait parmi les vingt-deux articles identifiés. La durée du suivi était de quelques mois à quatre ans. Trois rapports de cas et quatre études (trois études contrôlées et une étude d'observation) comportaient au total 246 patients évalués. Dans toutes les études, on a rapporté des observations relatives à la valvulopathie. Différentes méthodes ont été utilisées pour évaluer le degré de régurgitation valvulaire, ce qui rend difficile la comparaison entre les études. Il y a peu de données cliniques pour établir une corrélation avec les résultats d'échocardiographie. Chez les quelques patients chez qui on a cessé la médication, on a observé un degré variable d'amélioration. Il n'existe pas suffisamment de données pour déterminer si la dose et la durée d'administration ou d'autres comorbidités ont un effet sur le risque de développer une valvulopathie cardiaque.


Le traitement par le pergolide comporte un risque accru de développer une valvulopathie cardiaque, mais sa véritable incidence et son importance demeurent inconnues. La standardisation de l'évaluation de l'échocardiogramme devra faire l'objet d'études prospectives.

    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cardiac Valvulopathy Associated with Pergolide Use
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cardiac Valvulopathy Associated with Pergolide Use
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cardiac Valvulopathy Associated with Pergolide Use
      Available formats


Corresponding author

Gloria Shulman Movement Disorders Center, Toronto Western Hospital, 399 Bathurst Street, 7-McL, Toronto, Ontario, M5T 2S8, Canada.


Hide All
1. Lanier, WL. Additional insights into pergolide-associated valvularheart disease. Mayo Clin Proc. 2003; 78(6):684–6.
2. Gilbert, DL, Dure, L, Sethuraman, G, Raab, D, Lane, J, Sallee, FR. Ticreduction with pergolide in a randomized controlled trial inchildren. Neurology. 2003; 60(4):606–11.
3. Lipinski, JF, Sallee, FR, Jackson, C, Sethuraman, G. Dopamineagonist treatment of Tourette disorder in children: Results of an open-label trial of pergolide. Mov Disord. 1997; 12(3):402–7.
4. Pritchett, AM, Morrison, JF, Edwards, WD, Schaff, HV, Connolly, HM, Espinosa, RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002; 77(12):1280–6.
5. FDA 2003 Safety Alert – Permax. http:/ 2003.
6. Pergolide mesilate: strengthened warning. WHO drug information v17i1, 37. 2003.
8. Hendrikx, M, Van Dorpe, J, Flameng, W, Daenen, W. Aortic and mitralvalve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996; 5(2):235–7.
9. Redfield, MM, Nicholson, WJ, Edwards, WD, Tajik, AJ. Valve diseaseassociated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med. 1992; 117(1):50–2.
10. Flaherty, KR, Bates, JR. Mitral regurgitation caused by chronicergotamine use. Am Heart J. 1996; 131(3):603–6.
11. Connolly, HM, Crary, JL, McGoon, MD, Hensrud, DD, Edwards, BS, Edwards, WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337(9):581–8.
12. Robiolio, PA, Rigolin, VH, Wilson, JS, Harrison, JK, Sanders, LL, Bashore, TM, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995; 92(4): 790–5.
13. Millan, MJ, Maiofiss, L, Cussac, D, Audinot, V, Boutin, JA, Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2):791804.
14. Shaunak, S, Wilkins, A, Pilling, JB, Dick, DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry. 1999; 66(1):7981.
15. Jimenez-Jimenez, FJ, Lopez-Alvarez, J, Sanchez-Chapado, M, Montero, E, Miquel, J, Sierra, A, et al. Retroperitoneal fibrosis in a patient with Parkinson’s disease treated with pergolide. Clin Neuropharmacol. 1995; 18(3):277–9.
16. Mondal, BK, Suri, S. Pergolide-induced retroperitoneal fibrosis. Int JClin Pract. 2000; 54(6):403.
17. Agarwal, P, Fahn, S, Frucht, SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord. 2004; 19(6):699704.
18. Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):18961900.
19. Van Camp, G, Flamez, A, Cosyns, B, Goldstein, J, Perdaens, C, Schoors, D. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003; 61(6): 859–61.
20. Van Camp, G, Flamez, A, Cosyns, B, Weytjens, C, Muyldermans, L, Van Zandijcke, M, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004; 363(9416):1179–83.
21. Horvath, J, Fross, RD, Kleiner-Fisman, G, Lerch, R, Stalder, H, Liaudat, S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. MovDisord. 2004; 19(6):656–62.
22. Baseman, DG, O’Suilleabhain, PE, Reimold, SC, Laskar, SR, Baseman, JG, Dewey, RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004; 63(2):301–4.
23. Flowers, CM, Racoosin, JA, Lu, SL, Beitz, JG. The US Food and DrugAdministration’s registry of patients with pergolide-associatedvalvular heart disease. Mayo Clin Proc. 2003; 78(6):730–1.
24. Chaudhuri, KR, Dhawan, V, Basu, S, Jackson, G, Odin, P. Valvularheart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord. 2004; 19(12):1522–3.
25. Tanner, CM, Chhablani, R, Goetz, CG, Klawans, HL. Pergolidemesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology. 1985; 35(6):918–21.
26. Varsano, S, Gershman, M, Hamaoui, E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration. 2000; 67(5):580–2.
27. Leibowitz, M, Lieberman, A, Goldstein, M, Neophytides, A, Kupersmith, M, Gopinathan, G, et al. Cardiac effects of pergolide. Clin Pharmacol Ther. 1981; 30(6):718–23.
28. Grosset, KA, Grosset, DG. Pergolide in Parkinson’s disease: time fora change? Lancet. 2004; 363(9424):1907–8.
29. Valvular health disease with pergolide. Prescrire Int. 2003; 12(68):225.
30. Rahimtoola, SH. Drug-related valvular heart disease: here we goagain: will we do better this time? Mayo Clin Proc. 2002; 77(12):1275–7.
31. Rascol, O, Pathak, A, Bagheri, H, Montastruc, JL. New concerns aboutold drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord. 2004; 19(6):611–3.
32. Boudoulas, H. Etiology of valvular heart disease. Expert RevCardiovasc Ther. 2003; 1(4):523–32.
33. Boudoulas, H, Vavuranakis, M, Wooley, CF. Valvular heart disease:the influence of changing etiology on nosology. J Heart Valve Dis. 1994; 3(5):516–26.
34. Balachandran, KP, Stewart, D, Berg, GA, Oldroyd, KG. Chronicpericardial constriction linked to the antiparkinsonian dopamineagonist pergolide. Postgrad Med J. 2002; 78(915):4950.
35. Tintner, R, Manian, P, Gauthier, P, Jankovic, J. Pleuropulmonaryfibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005; 62(8): 1290–5.
36. Thalamas, C, Rajman, I, Kulisevsky, J, Lledo, A, Mackie, AE, Blin, O, et al. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol. 2005; 28(3):120–5.
37. Storch, A, Trenkwalder, C, Oehlwein, C, Winkelmann, J, Polzer, U, Hundemer, HP, et al. High-dose treatment with pergolide in Parkinson’s disease patients with motor fluctuations and dyskinesias. Parkinsonism Relat Disord. 2005.
38. Waller, EA, Kaplan, J, Heckman, MG. Valvular heart disease inpatients taking pergolide. Mayo Clin Proc. 2005; 80(8):1016–20.
39. Singh, JP, Evans, JC, Levy, D, Larson, MG, Freed, LA, Fuller, DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 83(6):897902.
40. Seghatol, FF, Rigolin, VH. Appetite suppressants and valvular heartdisease. Curr Opin Cardiol. 2002; 17(5):486–92.
41. Mast, ST, Jollis, JG, Ryan, T, Anstrom, KJ, Crary, JL. The progressionof fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med. 2001; 134(4):261–6.
42. Hensrud, DD, Connolly, HM, Grogan, M, Miller, FA, Bailey, KR, Jensen, MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 1999; 74(12):1191–7.
43. Donmez Colakoglu, B. Valvular heart disease in pergolide treatmentin Parkinson’s disease. Book of Abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.
44. Agmon, Y. Frequency of restrictive valvular heart disease in patientswith Parkinson’s disease treated with pergoide, an ergot derived anti-parkinsonian drug: a case-control echocardiography study. Book of abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.
45. Wolf, E. Valvular heart disease in Parkinson’s disease vs controls: anechocardiography study. Book of Abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.

Cardiac Valvulopathy Associated with Pergolide Use

  • Cindy Zadikoff (a1), Paula Rochon (a2) and Anthony Lang (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed